🌟 This marks a significant milestone for single-use bioreactor technology in Asia.
💰 The campaign achieved nearly 70% reduction in production costs and a 20% increase in protein yield.
🔄 WuXi’s innovative processes demonstrate a commitment to scalable, eco-friendly biomanufacturing.
Introduction:
WuXi Biologics has achieved a notable milestone by completing its first commercial Process Performance Qualification (PPQ) campaign at its Hangzhou facility. This achievement enhances their capabilities in large-scale biomanufacturing using single-use bioreactors, marking a significant advancement in the biopharmaceutical industry in Asia.
- WuXi Biologics completed a PPQ campaign for three sets of 5,000 L single-use bioreactors, representing the first of its kind in Asia.
- The successful campaign demonstrated the effectiveness of their single-use technology (SUT) in optimizing production processes.
- Production costs per gram of protein were reduced by nearly 70%, while protein yield per batch increased by 20% due to advanced mass transfer technology.
- In 2024, the company increased its production capacity from 8,000 L to 23,000 L by integrating the new bioreactors with existing production lines.
- WuXi Biologics’ continuous process innovation has led to a 99% production success rate across over 300 scaled production batches in recent years.
Conclusion:
The completion of the first commercial PPQ campaign signifies a major step forward for WuXi Biologics in biomanufacturing, paving the way for cost-effective and eco-friendly production practices. The company aims to leverage these advancements to enhance flexibility and patient options on a global scale, which could fundamentally shift the landscape of biopharmaceutical manufacturing.
